Lifevantage (LFVN) Competitors $13.98 +0.12 (+0.87%) Closing price 04:00 PM EasternExtended Trading$13.96 -0.02 (-0.11%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. ABUS, EOLS, RLAY, KROS, DNA, TYRA, PGEN, ARVN, TBPH, and SAGEShould you be buying Lifevantage stock or one of its competitors? The main competitors of Lifevantage include Arbutus Biopharma (ABUS), Evolus (EOLS), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), Ginkgo Bioworks (DNA), Tyra Biosciences (TYRA), Precigen (PGEN), Arvinas (ARVN), Theravance Biopharma (TBPH), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Lifevantage vs. Its Competitors Arbutus Biopharma Evolus Relay Therapeutics Keros Therapeutics Ginkgo Bioworks Tyra Biosciences Precigen Arvinas Theravance Biopharma Sage Therapeutics Lifevantage (NASDAQ:LFVN) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability. Is LFVN or ABUS more profitable? Lifevantage has a net margin of 4.12% compared to Arbutus Biopharma's net margin of -1,196.64%. Lifevantage's return on equity of 34.67% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Lifevantage4.12% 34.67% 15.24% Arbutus Biopharma -1,196.64%-75.51%-55.81% Do analysts rate LFVN or ABUS? Lifevantage currently has a consensus target price of $30.50, suggesting a potential upside of 118.17%. Arbutus Biopharma has a consensus target price of $5.50, suggesting a potential upside of 69.75%. Given Lifevantage's higher probable upside, analysts clearly believe Lifevantage is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, LFVN or ABUS? Lifevantage has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifevantage$222.35M0.79$2.94M$0.6920.26Arbutus Biopharma$6.17M100.58-$69.92M-$0.41-7.90 Does the media refer more to LFVN or ABUS? In the previous week, Lifevantage had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Lifevantage and 1 mentions for Arbutus Biopharma. Lifevantage's average media sentiment score of 1.16 beat Arbutus Biopharma's score of 0.00 indicating that Lifevantage is being referred to more favorably in the media. Company Overall Sentiment Lifevantage Positive Arbutus Biopharma Neutral Do institutionals & insiders have more ownership in LFVN or ABUS? 35.3% of Lifevantage shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 20.7% of Lifevantage shares are held by insiders. Comparatively, 20.3% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, LFVN or ABUS? Lifevantage has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. SummaryLifevantage beats Arbutus Biopharma on 11 of the 15 factors compared between the two stocks. Get Lifevantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifevantageMED/DENTAL IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.47M$15.72B$5.70B$9.48BDividend Yield1.39%1.42%4.59%3.99%P/E Ratio20.2619.1627.9019.95Price / Sales0.792.45442.19102.72Price / Cash15.7117.5736.5558.97Price / Book6.824.058.635.90Net Income$2.94M$430.42M$3.24B$258.42M7 Day Performance5.03%4.33%3.22%1.94%1 Month Performance14.22%5.83%10.72%12.02%1 Year Performance101.73%17.27%34.94%20.81% Lifevantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifevantage4.3403 of 5 stars$13.98+0.9%$30.50+118.2%+110.0%$174.47M$222.35M20.26260Positive NewsABUSArbutus Biopharma1.5879 of 5 stars$3.24+2.2%$5.50+69.8%-15.7%$620.56M$6.17M-7.9090EOLSEvolus3.7168 of 5 stars$9.51+0.3%$23.75+149.7%-23.9%$613.21M$266.27M-10.69170News CoverageRLAYRelay Therapeutics1.9784 of 5 stars$3.56-1.1%$17.67+396.3%-60.0%$610.36M$10.01M-1.60330KROSKeros Therapeutics1.594 of 5 stars$14.57+0.9%$30.56+109.7%-71.6%$591.83M$3.55M-80.94100DNAGinkgo Bioworks0.9537 of 5 stars$9.91-0.7%$8.50-14.3%N/A$580.29M$237.42M-1.08640News CoverageGap DownTYRATyra Biosciences2.7902 of 5 stars$10.91+6.3%$30.83+182.6%-50.4%$579.21MN/A-6.6920PGENPrecigen4.0477 of 5 stars$1.95+6.6%$6.00+207.7%+0.6%$575.60M$4.20M-3.48190News CoveragePositive NewsARVNArvinas3.7529 of 5 stars$7.87+1.0%$20.29+157.8%-73.8%$574.43M$263.40M-11.92420News CoverageUpcoming EarningsTBPHTheravance Biopharma1.8014 of 5 stars$11.47+1.5%$16.60+44.7%+12.1%$573.50M$64.38M-9.72110SAGESage Therapeutics3.3405 of 5 stars$9.15-1.3%$8.75-4.4%-33.0%$572.97M$41.24M-1.58690Upcoming Earnings Related Companies and Tools Related Companies Arbutus Biopharma Competitors Evolus Competitors Relay Therapeutics Competitors Keros Therapeutics Competitors Ginkgo Bioworks Competitors Tyra Biosciences Competitors Precigen Competitors Arvinas Competitors Theravance Biopharma Competitors Sage Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifevantage Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifevantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
